Tag: Hudson Institute of Medical Research
ASX biotech firm Noxopharm unveils anti-inflammatory skin disease drug
Australian biotech company Noxopharm Limited unveiled today its new preclinical product candidate from its Sofra technology platform that has shown effectiveness against inflammatory skin disease in preclinical models
ASX biotech firm Noxopharm’s new mRNA enhancer to make vaccines safer
Australian biotech company Noxopharm Limited unveiled today the development of a new mRNA vaccine enhancer that will make mRNA vaccines safer by reducing inflammation associated with mRNA vaccines.Â
Featured Article
Navigating energy price volatility with predictive intelligence
Energy price volatility has become a structural feature of modern electricity markets rather than a temporary disruption. For energy-intensive manufacturers and large commercial operators, fluctuating wholesale prices are reshaping how energy costs are managed, making reactive approaches increasingly inadequate.
